Edition:
India

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

12.22USD
10:52pm IST
Change (% chg)

$0.29 (+2.43%)
Prev Close
$11.93
Open
$12.08
Day's High
$12.33
Day's Low
$11.85
Volume
59,143
Avg. Vol
375,406
52-wk High
$21.19
52-wk Low
$11.03

Latest Key Developments (Source: Significant Developments)

Approval Of Linzess Tablets 0.25 Mg In Japan For Additional Indication Of Chronic Constipation
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Ironwood Pharmaceuticals Inc ::APPROVAL OF LINZESS TABLETS 0.25 MG IN JAPAN FOR ADDITIONAL INDICATION OF CHRONIC CONSTIPATION.IRONWOOD PHARMA - IMPACT OF APPROVAL OF ADDITIONAL CHRONIC CONSTIPATION INDICATION FACTORED INTO FINANCIAL FORECAST FOR FY ENDING MARCH 2019.  Full Article

Ironwood Pharmaceuticals Reports Qtrly Adjusted Loss Per Share $0.28
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS PROVIDES SECOND QUARTER 2018 INVESTOR UPDATE.Q2 REVENUE $81 MILLION VERSUS I/B/E/S VIEW $82.6 MILLION.QTRLY LOSS PER SHARE $0.32.QTRLY ADJUSTED LOSS PER SHARE $0.28.TERMINATING LICENSING AGREEMENT WITH ASTRAZENECA FOR U.S. LESINURAD FRANCHISE.IRONWOOD - ON TRACK TO COMPLETE SEPARATION OF IRONWOOD INTO TWO PUBLICLY TRADED COS IN H1 2019.ON TRACK TO COMPLETE SEPARATION OF CO INTO TWO INDEPENDENT, PUBLICLY TRADED COMPANIES IN H1 2019.PLANS TO REDUCE ITS WORKFORCE BY ABOUT 125 EMPLOYEES.IRONWOOD PHARMACEUTICALS - ESTIMATES WILL INCUR AGGREGATE CHARGES IN CONNECTION WITH REDUCTION IN WORKFORCE OF ABOUT $10 MILLION TO $13 MILLION IN 2018.NO LONGER EXPECTS TO BE CASH FLOW POSITIVE IN Q4 OF 2018 DUE TO RESTRUCTURING COSTS.NOW EXPECTS IN 2018 RESTRUCTURING COSTS OF $18 MILLION TO $21 MILLION.IRONWOOD - EXPECTS TO SAVE ABOUT $75 MILLION TO $100 MILLION IN 2019 OPERATING. EXPENSES, PRIMARILY WITHIN SG&A.  Full Article

Ironwood Pharmaceuticals Determined Initial Organizational Designs Of Two New Businesses
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - DETERMINED INITIAL ORGANIZATIONAL DESIGNS OF TWO NEW BUSINESSES, INCLUDING EMPLOYEES' ROLES AND RESPONSIBILITIES.IRONWOOD PHARMACEUTICALS- AS PART OF INITIAL ORGANIZATIONAL DESIGNS PROCESS, CO COMMENCED IMPLEMENTATION OF REDUCTION IN WORKFORCE BY ABOUT 40 EMPLOYEES.IRONWOOD PHARMA - INITIAL ORGANIZATIONAL DESIGNS RELATED TO INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS.IRONWOOD PHARMACEUTICALS-ESTIMATES THAT IN CONNECTION WITH REDUCTION IN WORKFORCE TO INCUR CHARGES OF ABOUT $5.0 MILLION TO $5.5 MILLION.IRONWOOD PHARMACEUTICALS - EXPECTS TO SUBSTANTIALLY COMPLETE REDUCTION IN ITS WORKFORCE DURING YEAR ENDING DECEMBER 31, 2018.  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017.IRONWOOD PHARMACEUTICALS - ‍EXPECTED IRONWOOD REVENUE FROM LINACLOTIDE API SALES TO ASTELLAS OF MORE THAN $100 MILLION FROM JAN 1, 2017 TO DEC 31, 2019​.IRONWOOD PHARMACEUTICALS- EXPECTED REVENUE CAGR FROM THE LINZESS U.S. COLLABORATION WITH ALLERGAN OF ABOUT 75% FOR YEAR ENDED DEC 31, 2014 TO 2017.IRONWOOD PHARMACEUTICALS- EXPECTED LINZESS U.S. NET SALES CAGR OF GREATER THAN 30% FOR YEAR ENDED DEC 31, 2014 TO YEAR ENDED DECEMBER 31, 2017.  Full Article

Ironwood Pharmaceuticals Strengthens Executive Leadership Team
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ironwood Pharmaceuticals Inc ::IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM.IRONWOOD PHARMACEUTICALS INC - PROMOTED ‍ GINA CONSYLMAN TO SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER​.  Full Article

Ironwood Pharma files for potential mixed shelf offering
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing‍​.  Full Article

Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ironwood Pharmaceuticals Inc :Q3 non-GAAP loss per share $0.18.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.Ironwood Pharmaceuticals provides third quarter 2017 investor update.Q3 loss per share $0.22.Q3 revenue $87 million versus I/B/E/S view $73.6 million.Ironwood Pharmaceuticals Inc sees 2017 ‍R&D expenses to be in low-to-middle end of previously guided $145 million to $160 million range​.Ironwood Pharmaceuticals Inc - ‍data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017​.Ironwood Pharmaceuticals Inc - ‍to use less than $110 million in cash for operations in 2017, up from less than $100 million previously guided​.Ironwood - sees co & Allergan's ‍combined total 2017 marketing & sales expenses for Linzess in middle of previously guided $250 million to $280 million range​.Ironwood Pharmaceuticals Inc - co & Allergan no longer intend to pursue linaclotide delayed release-1​.  Full Article